Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ascentage Pharma Group International ( (HK:6855) ) has provided an update.
Ascentage Pharma announced that it will present the latest results from multiple clinical studies of its investigational drug candidates at the 67th American Society of Hematology (ASH) Annual Meeting in 2025. The presentations will include data on olverembatinib, a third-generation BCR-ABL inhibitor, and lisaftoclax, a Bcl-2 inhibitor, highlighting their potential in treating various hematologic malignancies. This participation underscores Ascentage Pharma’s ongoing commitment to advancing cancer therapies and its strong presence in the international hematology community.
The most recent analyst rating on (HK:6855) stock is a Hold with a HK$63.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International stock, see the HK:6855 Stock Forecast page.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company focused on developing innovative therapies for cancer, chronic hepatitis B, and age-related diseases. The company is known for its investigational drug candidates, including olverembatinib, lisaftoclax, and APG-5918, which target specific pathways in cancer treatment. Ascentage Pharma collaborates with Innovent Biologics, Inc. to commercialize its products in China.
Average Trading Volume: 3,269,959
Technical Sentiment Signal: Buy
Current Market Cap: HK$24.63B
See more data about 6855 stock on TipRanks’ Stock Analysis page.